[go: up one dir, main page]

NO962130D0 - Synergistisk behandling av Parkinsons sykdom - Google Patents

Synergistisk behandling av Parkinsons sykdom

Info

Publication number
NO962130D0
NO962130D0 NO962130A NO962130A NO962130D0 NO 962130 D0 NO962130 D0 NO 962130D0 NO 962130 A NO962130 A NO 962130A NO 962130 A NO962130 A NO 962130A NO 962130 D0 NO962130 D0 NO 962130D0
Authority
NO
Norway
Prior art keywords
disease
parkinson
synergistic treatment
relates
combination
Prior art date
Application number
NO962130A
Other languages
English (en)
Other versions
NO962130L (no
Inventor
Bertrand L Chenard
Frank S Menniti
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO962130D0 publication Critical patent/NO962130D0/no
Publication of NO962130L publication Critical patent/NO962130L/no

Links

Classifications

    • G—PHYSICS
    • G10—MUSICAL INSTRUMENTS; ACOUSTICS
    • G10H—ELECTROPHONIC MUSICAL INSTRUMENTS; INSTRUMENTS IN WHICH THE TONES ARE GENERATED BY ELECTROMECHANICAL MEANS OR ELECTRONIC GENERATORS, OR IN WHICH THE TONES ARE SYNTHESISED FROM A DATA STORE
    • G10H5/00—Instruments in which the tones are generated by means of electronic generators
    • G10H5/10—Instruments in which the tones are generated by means of electronic generators using generation of non-sinusoidal basic tones, e.g. saw-tooth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Multimedia (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Hydrogenated Pyridines (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
NO962130A 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom NO962130L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB1995/000398 WO1996037226A2 (en) 1995-05-26 1995-05-26 Combinations for the treatment of parkinsonism containing selective nmda antagonists
HU9601419A HUP9601419A3 (en) 1995-05-26 1996-05-24 Synergetic pharmaceutical compositions for treating parkinson-disease

Publications (2)

Publication Number Publication Date
NO962130D0 true NO962130D0 (no) 1996-05-24
NO962130L NO962130L (no) 1996-11-27

Family

ID=89994003

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962130A NO962130L (no) 1995-05-26 1996-05-24 Synergistisk behandling av Parkinsons sykdom

Country Status (26)

Country Link
US (1) US6258827B1 (no)
EP (1) EP0828513B1 (no)
JP (1) JPH11505828A (no)
CN (1) CN1159325A (no)
AT (1) ATE258067T1 (no)
AU (1) AU696258B2 (no)
BR (1) BR9602485A (no)
CA (1) CA2219911C (no)
CO (1) CO4700422A1 (no)
CZ (1) CZ283979B6 (no)
DE (1) DE69532482T2 (no)
DK (1) DK0828513T3 (no)
ES (1) ES2211904T3 (no)
FI (1) FI974323A0 (no)
HU (1) HUP9601419A3 (no)
IL (1) IL118328A (no)
MX (1) MX9709112A (no)
NO (1) NO962130L (no)
NZ (1) NZ286656A (no)
PL (1) PL314413A1 (no)
PT (1) PT828513E (no)
RU (1) RU2176145C2 (no)
SG (1) SG45479A1 (no)
TR (1) TR199600436A2 (no)
TW (1) TW470740B (no)
WO (1) WO1996037226A2 (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
WO1999021539A1 (en) * 1997-10-24 1999-05-06 Warner-Lambert Company Method for treating disease-related or drug-induced dyskinesias
US6380205B1 (en) 1999-10-29 2002-04-30 Merck & Co., Inc. 2-cyclohexyl quinazoline NMDA/NR2B antagonists
US6495561B2 (en) 1999-10-29 2002-12-17 Merck & Co., Inc. 2-cyclohexyl imidazopyridine NMDA/NR2B antagonists
US6432976B1 (en) 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
CA2386441A1 (en) 1999-10-29 2001-05-03 Merck Sharp & Dohme Limited Method to treat pain utilizing benzimidazole nmda/nr2b antagonists
US6291499B1 (en) 1999-10-29 2001-09-18 Merck & Co., Inc. 2-cyclohexyl benzimidazole NMDA/NR2B antagonists
US6476041B1 (en) 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
US6489477B1 (en) 1999-10-29 2002-12-03 Merck & Co., Inc. 2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists
US6369076B1 (en) 1999-10-29 2002-04-09 Merck & Co. Inc. 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists
EP1186303A3 (en) * 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
US7217716B2 (en) 2001-02-23 2007-05-15 Merck & Co., Inc. N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists
WO2002069974A1 (en) * 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
CA2440284A1 (en) * 2001-03-08 2002-09-19 Emory University Ph-dependent nmda receptor antagonists
US7259157B2 (en) 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
US20030045449A1 (en) * 2001-08-15 2003-03-06 Pfizer, Inc. Pharmaceutical combinations for the treatment of neurodegenerative diseases
DE10142176A1 (de) * 2001-08-29 2003-03-27 Eucro Europe Contract Res Gmbh Verwendung einer Kombination aus ß-adrenergen Agonisten und NDMA-Antagonisten
WO2003062235A1 (en) * 2002-01-17 2003-07-31 Eli Lilly And Company Modulators of acetylcholine receptors
US6743921B2 (en) * 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
US20040116436A1 (en) * 2002-10-08 2004-06-17 Tatton William G. Treatment of dementia and parkinson's disease
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
US20070010584A1 (en) * 2003-09-04 2007-01-11 Peroutka Stephen J Compositions and methods for orthostatic intolerance
CA2537765A1 (en) * 2003-09-04 2005-03-17 Board Of Regents, The University Of Texas System Methods and compositions for the prevention and treatment of genitourinary disorders, including pre-term labor and leiomyomas
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP1799264A2 (en) * 2004-10-08 2007-06-27 Neuromolecular Pharmaceuticals Inc Methods and compositions for treating migraine pain
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1838705A2 (en) * 2005-01-13 2007-10-03 Neurosearch A/S 3,8-substituted 8-aza-bicyclo [3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2006121560A2 (en) * 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20070118044A1 (en) * 2005-07-18 2007-05-24 Mega Elektroniikka Oy Method and device for identifying; measuring and analyzing abnormal neurological responses
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RU2324492C1 (ru) * 2006-12-04 2008-05-20 Общество с ограниченной ответственностью "Березовый мир" Средство для профилактики и лечения болезни паркинсона
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
PT2303330T (pt) * 2008-06-06 2018-02-12 Pharma Two B Ltd Composições farmacêuticas para o tratamento da doença de parkinson
US8648198B2 (en) 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
CA2869216A1 (en) * 2012-04-20 2013-10-24 Ucb Pharma S.A. Methods for treating parkinson's disease
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN106413754B (zh) 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
CA2108557A1 (en) 1991-04-18 1992-10-19 Bertrand L. Chenard Prodrug esters of phenolic 2-piperidino-1-alkanols
DE4118740A1 (de) * 1991-06-05 1992-12-10 Schering Ag Neue kombinationspraeparate zur behandlung des morbus parkinson

Also Published As

Publication number Publication date
CZ283979B6 (cs) 1998-07-15
PL314413A1 (en) 1996-12-09
BR9602485A (pt) 1998-04-22
US6258827B1 (en) 2001-07-10
WO1996037226A3 (en) 1996-12-27
PT828513E (pt) 2004-05-31
CZ152496A3 (cs) 1998-04-15
CN1159325A (zh) 1997-09-17
TR199600436A2 (tr) 1996-12-21
EP0828513B1 (en) 2004-01-21
IL118328A (en) 2001-06-14
FI974323A (fi) 1997-11-25
CO4700422A1 (es) 1998-12-29
DE69532482D1 (de) 2004-02-26
IL118328A0 (en) 1996-09-12
ATE258067T1 (de) 2004-02-15
DK0828513T3 (da) 2004-04-13
EP0828513A2 (en) 1998-03-18
HUP9601419A3 (en) 1998-01-28
CA2219911A1 (en) 1996-11-28
DE69532482T2 (de) 2004-11-25
NZ286656A (en) 2001-03-30
ES2211904T3 (es) 2004-07-16
AU696258B2 (en) 1998-09-03
TW470740B (en) 2002-01-01
HU9601419D0 (en) 1996-07-29
RU2176145C2 (ru) 2001-11-27
SG45479A1 (en) 1998-01-16
NO962130L (no) 1996-11-27
CA2219911C (en) 2004-07-27
JPH11505828A (ja) 1999-05-25
FI974323A0 (fi) 1997-11-25
HUP9601419A2 (en) 1997-09-29
WO1996037226A2 (en) 1996-11-28
AU5451996A (en) 1996-12-05
MX9709112A (es) 1998-02-28

Similar Documents

Publication Publication Date Title
NO962130D0 (no) Synergistisk behandling av Parkinsons sykdom
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
ATE230989T1 (de) Anabasein derivate zur behandlung von degenerativen erkrankungen des nervensystems
IL143313A0 (en) Compositions and methods for the treatment of alzheimer's disease, central nervous system injury, and inflammatory diseases
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
MY121036A (en) Piperazinyl-heterocyclic compounds in the treatment of dementia.
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE144898T1 (de) Behandlung neurodegenerativer krankheiten
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
EA200200847A1 (ru) Производные пиперазина и пиперидина для лечения и профилактики поврежденных нейронов
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AUPP674898A0 (en) A method of treatment
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE113591T1 (de) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol- - one und ihre verwendung als antikonvulsiva.
DE69926794D1 (de) Ponazuril zur behandlung von durch coccidia neurologischen und "abortigenic" verursachten erkrankungen
MY118944A (en) Synergistic treatment for parkinsonism
MY121206A (en) Aminobenzamide compounds for the treatment of neurodegenerative disorders
DE69916577D1 (de) Azetidincarboxamid-derivate zur behandlung von zns störungen
ATE242766T1 (de) Neue derivate von benzoylalkyl-1,2,3,6- tetrahydropyridinen
MX9701528A (es) Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer.